ArticleMolecular biotechnology2022
LncRNA-TUG1 Downregulation is Correlated with the Development of Progressive Chronic Kidney Disease Among Patients with Congestive Heart Failure.
Article in Molecular biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Spectrometry and Its Application for the Detection of RNA-Binding Proteins: Advancements, Techniques and Challenges.Analytical science advances · 2025Review
- lncRNA TUG1 and kidney diseases.BMC nephrology · 2025Review
- HCG18 Promotes Cell Proliferation and Stemness in Cholangiocarcinoma via the miR-194-5p/KRT18/MAPK Signaling.Biochemical genetics · 2025Article
- Novel dysregulated long non-coding RNAs in the acute kidney injury-to-chronic kidney diseases transition unraveled by transcriptomic analysis.Pharmacology research & perspectives · 2024Article
- LncRNA HCG18 Promotes Osteosarcoma Cells Proliferation, Migration, and Invasion in by Regulating miR-34a/RUNX2 Pathway.Biochemical genetics · 2023Article
- Predictive value of serum human epididymis protein 4 for heart failure in patients with chronic kidney disease.American journal of translational research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TUG1 is an lncRNA that plays a critical role in kidney injury. Our preliminary sequencing analysis showed altered TUG1 expression in both congestive heart failure (CHF) patients and CHF patients complicated with chronic kidney disease (CKD). We then studied the role of TUG1 in these two diseases. We enrolled 120 CHF patients without obvious complications, 60 CHF patients complicated with CKD, and 60 healthy volunteers. TUG1 expression in plasma samples from these participants was determined using RT-qPCR. The diagnostic value of TUG1 for CKD development in CHF patients was evaluated by ROC curve analysis. A 2-year follow-up was performed to detect the correlation between TUG1 expression levels and the development of CKD in CHF. TUG1 was lowly expressed in CHF patients and was further downregulated in CHF patients complicated with progressive CKD. ROC curve analysis showed that plasma TUG1 expression levels could be used to distinguish CHF patients complicated with CKD from CHF patients without CKD and healthy controls. During the 2-year follow-up, high CHF expression levels predicted a low incidence of progressive CKD among CHF patients. With the treatment of progressive CHF + CKD, plasma TUG1 was upregulated. LncRNA-TUG1 downregulation may develop the progressive CKD among patients with CHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.